Loading data
DERMNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 61.24 m USD | 55.13 m USD | 59.66 m USD | 71 m USD | 63.13 m USD |
| Cost of revenue | 20.92 m USD | 20.88 m USD | 22.89 m USD | 30.78 m USD | 32.08 m USD |
| Research and development expense | 480 k USD | 9.86 m USD | 7.54 m USD | 10.94 m USD | 2.74 m USD |
| Selling, general and administrative expense | 44.37 m USD | 40.2 m USD | 43.91 m USD | 59.47 m USD | 39.83 m USD |
| Operating profit | -8.17 m USD | -13.68 m USD | -2.07 m USD | -27.52 m USD | -34.88 m USD |
| Interest expense | — | — | 1.7 m USD | 2.02 m USD | 7.03 m USD |
| Profit before tax | -11.37 m USD | -14.61 m USD | -3.63 m USD | -29.57 m USD | -42.36 m USD |
| Income tax expense | 60 k USD | 61 k USD | 221 k USD | 63 k USD | 1.63 m USD |
| Net income (reported basis) | -11.43 m USD | -14.67 m USD | -3.85 m USD | -29.63 m USD | -43.99 m USD |
| Basic earnings per share | -0.47 USD/share | -0.72 USD/share | -0.21 USD/share | -1.69 USD/share | -4.32 USD/share |
| Diluted earnings per share | -0.47 USD/share | -0.72 USD/share | -0.21 USD/share | -1.69 USD/share | -4.32 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.